HerzKlinik Hirslanden, Zürich, Switzerland.
Praxis für Naturheilverfahren, Bad Camberg, Germany.
Sci Rep. 2024 Oct 3;14(1):22986. doi: 10.1038/s41598-024-74325-4.
Hawthorn special extract WS 1442 has beneficial effects on the cardiovascular system. Experimental studies have shown an antiarrhythmic effect of the substance. In the present study, we investigated antiarrhythmic effects of WS 1442 compared with magnesium/potassium in a large collective of outpatients. Using the IQVIA Disease Analyzer (DA) database, we included 4550 patients with a prescription of WS 1442 and 4550 matched patients with Tromcardin prescriptions (all registered products under the trademark Tromcardin that are magnesium and potassium supplementing foods for special medical purposes) who were followed for 5 years after the index date. The incidence of various cardiac arrhythmias (atrial fibrillation and flutter (AFF), tachycardia, and other cardiac arrhythmias) was recorded. Cox regression models were used to evaluate the potential association between both drugs and arrhythmias. The cumulative incidence of atrial fibrillation and flutter was significantly lower among patients with a prescription of WS 1442 compared to patients with magnesium/potassium prescriptions (10.8% vs. 16.4%, p < 0.001). WS 1442 prescription was significantly associated with a lower incidence of atrial fibrillation and flutter compared to magnesium/potassium (HR 0.71; 95% CI 0.64-0.80; p < 0.001). The cumulative incidence of tachycardia was significantly lower in the WS 1442 group compared to the magnesium/potassium group (8.3% vs. 9.4%, p < 0.001), similarly, the cumulative incidence of other cardiac arrhythmias was significantly lower among patients with WS 1442 compared to patients with magnesium/potassium (10.2% vs. 14.8%, p < 0.001). This study showed that in a large collective of outpatients, intake of hawthorn special extract WS 1442 was associated with a significantly lower incidence of atrial fibrillation, tachycardia, and other cardiac arrhythmias compared to magnesium/potassium, indicating its potential in treating and preventing such conditions.
山楂特殊提取物 WS 1442 对心血管系统有有益的影响。实验研究表明该物质具有抗心律失常作用。在本研究中，我们研究了 WS 1442 与镁/钾相比在大量门诊患者中的抗心律失常作用。使用 IQVIA 疾病分析器 (DA) 数据库，我们纳入了 4550 例 WS 1442 处方患者和 4550 例 Tromcardin 处方匹配患者（所有 Tromcardin 注册产品均为镁和钾补充特殊医学用途食品），在索引日期后随访 5 年。记录各种心律失常（心房颤动和扑动 (AFF)、心动过速和其他心律失常）的发生率。Cox 回归模型用于评估两种药物与心律失常之间的潜在关联。与镁/钾处方相比，WS 1442 处方患者心房颤动和扑动的累积发生率明显较低（10.8% vs. 16.4%，p<0.001）。与镁/钾相比，WS 1442 处方与心房颤动和扑动发生率较低显著相关（HR 0.71；95%CI 0.64-0.80；p<0.001）。WS 1442 组心动过速的累积发生率明显低于镁/钾组（8.3% vs. 9.4%，p<0.001），同样，WS 1442 组其他心律失常的累积发生率明显低于镁/钾组（10.2% vs. 14.8%，p<0.001）。本研究表明，在大量门诊患者中，与镁/钾相比，摄入山楂特殊提取物 WS 1442 与心房颤动、心动过速和其他心律失常的发生率显著降低相关，表明其在治疗和预防此类疾病方面的潜力。
